RV7 주식 개요 바이오 제약 기술 플랫폼 회사인 Halozyme Therapeutics는 미국, 스위스, 벨기에, 일본 및 전 세계에서 독점 효소 및 장치를 연구, 개발 및 상용화하는 기업입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Halozyme Therapeutics, Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Halozyme Therapeutics 과거 주가 현재 주가 US$45.49 52주 최고치 US$58.18 52주 최저치 US$30.78 베타 1.24 1개월 변경 -0.70% 3개월 변경 사항 -10.52% 1년 변경 사항 37.64% 3년 변화 27.39% 5년 변화 187.91% IPO 이후 변화 1,977.17%
최근 뉴스 및 업데이트
New minor risk - Share price stability Nov 15 Halozyme Reportedly Interested in Acquiring Evotec for $2.1 Billion
Investor sentiment improves as stock rises 20% Nov 07
Third quarter 2024 earnings released: EPS: US$1.08 (vs US$0.62 in 3Q 2023) Nov 01
Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2024 Nov 01
Halozyme Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 24 더 많은 업데이트 보기
New minor risk - Share price stability Nov 15 Halozyme Reportedly Interested in Acquiring Evotec for $2.1 Billion
Investor sentiment improves as stock rises 20% Nov 07
Third quarter 2024 earnings released: EPS: US$1.08 (vs US$0.62 in 3Q 2023) Nov 01
Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2024 Nov 01
Halozyme Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 24
Investor sentiment deteriorates as stock falls 16% Oct 11 Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis Sep 14
Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer Sep 13
Independent Director recently sold €1.5m worth of stock Aug 15
Second quarter 2024 earnings released: EPS: US$0.73 (vs US$0.57 in 2Q 2023) Aug 07
Halozyme Therapeutics, Inc. Reiterates Financial Guidance for 2024 Aug 07
Halozyme Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 23
Halozyme Therapeutics, Inc. Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis Jun 25
Halozyme Therapeutics, Inc. Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy Jun 22
Independent Director recently sold €928k worth of stock Jun 15
Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2024 Jun 08
Investor sentiment improves as stock rises 19% Jun 07
First quarter 2024 earnings released: EPS: US$0.60 (vs US$0.29 in 1Q 2023) May 08
Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024 May 08
Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors Apr 27
Halozyme Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 24
Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024 Mar 16
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024 Feb 21
Full year 2023 earnings released: EPS: US$2.13 (vs US$1.48 in FY 2022) Feb 21 Halozyme Therapeutics, Inc. (NasdaqGS:HALO) announces an Equity Buyback for $750 million worth of its shares. Feb 21
Halozyme Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024 Feb 09
Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis Jan 19
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023 Jan 18
Halozyme Announces Takeda Receives FDA Approval for Hyqvia® Co-Formulated with Enhanze® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy Jan 17
Halozyme Announces Roche Receives European Commission Approval of Tecentriq®? SC with ENHANZE®? Representing the EU's First Subcutaneous PD(L)1 Cancer Immunotherapy for Multiple Cancer Types Jan 16
Third quarter 2023 earnings released: EPS: US$0.62 (vs US$0.45 in 3Q 2022) Nov 07
Halozyme Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 31
Halozyme Therapeutics, Inc. Reports Positive Topline Results from the Phase 3 Checkmate-67T Trial Evaluating Subcutaneous (SC) Formulation of Opdivo (Nivolumab) with Enhanze Oct 20
Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery Oct 17
Halozyme Therapeutics, Inc Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain Aug 30
Independent Director recently sold €801k worth of stock Aug 17
Second quarter 2023 earnings released: EPS: US$0.57 (vs US$0.16 in 2Q 2022) Aug 09
Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023 Aug 09
Halozyme Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy Jul 17
Positive Results Announces from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis Jul 13 Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo With ENHANZE for Subcutaneous Use in Generalized Myasthenia Gravis Jun 21
First quarter 2023 earnings released: EPS: US$0.29 (vs US$0.44 in 1Q 2022) May 10
Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2023 May 10
Insufficient new directors Mar 27
Investor sentiment deteriorates as stock falls 16% Mar 17
Independent Director recently sold €902k worth of stock Mar 06
Full year 2022 earnings released: EPS: US$1.48 (vs US$2.86 in FY 2021) Feb 22
Halozyme Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023 Feb 08
Halozyme Therapeutics Appoints Barbara Duncan to Its Board of Directors Feb 07
Halozyme Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2023 Jan 11
Independent Director recently sold €1.6m worth of stock Dec 09
CFO & Director recently sold €259k worth of stock Nov 17
Third quarter 2022 earnings released: EPS: US$0.45 (vs US$1.53 in 3Q 2021) Nov 10
Halozyme Therapeutics, Inc. Reiterates Financial Guidance for the Year 2022 Nov 09
Halozyme Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Second quarter 2022 earnings released: EPS: US$0.16 (vs US$0.64 in 2Q 2021) Aug 11
Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2022 Aug 10
Halozyme Therapeutics, Inc. Announces Positive Results from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq with ENHANZE in Advanced Non-Small Cell Lung Cancer Aug 02
Halozyme Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
Investor sentiment improved over the past week Jul 09
Halozyme Therapeutics, Inc. Announces Commercial Launch of TLANDO, an Oral Treatment for Testosterone Replacement Therapy Jun 09
Halozyme Therapeutics, Inc. (NasdaqGS:HALO) completed the acquisition of Antares Pharma, Inc. (NasdaqCM:ATRS). May 25
Investor sentiment improved over the past week May 19
Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022 May 12
First quarter 2022 earnings released: EPS: US$0.44 (vs US$0.20 in 1Q 2021) May 11
Halozyme Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022 May 04
Insufficient new directors Apr 27 Halozyme Therapeutics, Inc. (NasdaqGS:HALO) entered into a definitive agreement to acquire Antares Pharma, Inc. (NasdaqCM:ATRS) for $970 million. Apr 15
Halozyme Therapeutics, Inc. (NasdaqGS:HALO) entered into a definitive agreement to acquire Antares Pharma, Inc. (NasdaqCM:ATRS) for $970 million. Apr 14
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022 Feb 24
Halozyme Therapeutics, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 10
Halozyme Therapeutics, Inc. Announces Executive Changes Feb 04
Halozyme Therapeutics, Inc. Announces Change of Chief Financial Officer Feb 03
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2022 Jan 12
Investor sentiment improved over the past week Dec 18
Halozyme Therapeutics, Inc. (NasdaqGS:HALO) announces an Equity Buyback for $750 million worth of its shares. Dec 10
Independent Chairperson of the Board recently sold €1.1m worth of stock Nov 07
Third quarter 2021 earnings released: EPS US$1.53 (vs US$0.27 in 3Q 2020) Nov 04
Insufficient new directors Nov 01
Insufficient new directors Oct 02
Independent Director recently sold €1.2m worth of stock Aug 27
Second quarter 2021 earnings released: EPS US$0.64 (vs US$0.19 in 2Q 2020) Aug 10
Halozyme Therapeutics, Inc. Announces Janssen Receives European Marketing Authorizations for Darzalex® (Daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-Chain Amyloidosis and Pre-Treated Multiple Myeloma Jun 23
First quarter 2021 earnings released: EPS US$0.20 (vs US$0.044 loss in 1Q 2020) May 12
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year of 2021 May 11
Independent Director has left the company May 07 주주 수익률 RV7 DE Biotechs DE 마켓 7D 1.0% 1.2% -0.3% 1Y 37.6% -14.3% 7.0%
전체 주주 수익률 보기
수익률 대 산업: RV7 지난 1년 동안 -14.3 %를 반환한 German Biotechs 산업을 초과했습니다.
수익률 대 시장: RV7 지난 1년 동안 7 %를 반환한 German 시장을 초과했습니다.
가격 변동성 Is RV7's price volatile compared to industry and market? RV7 volatility RV7 Average Weekly Movement 9.2% Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: RV7 의 주가는 지난 3개월 동안 변동성이 심했습니다.
시간에 따른 변동성: RV7 의 주간 변동성 ( 9% )은 지난 1년 동안 안정적이었지만 여전히 German 의 75%보다 높습니다. 주식.
회사 소개 바이오 제약 기술 플랫폼 회사인 Halozyme Therapeutics는 미국, 스위스, 벨기에, 일본 및 전 세계에서 독점 효소와 장치를 연구, 개발 및 상용화하고 있습니다. 이 회사의 제품은 특허받은 재조합 인간 히알루로니다제 효소(rHuPH20)를 기반으로 단일 클론 항체 및 기타 치료 분자는 물론 소분자 및 체액과 같은 주사 가능한 생물학적 제제를 전달할 수 있도록 합니다. 이 제품은 피하(SC) 수액 투여를 용이하게 하여 수분을 공급함으로써 SC 비뇨기과에서 다른 주사 약물의 분산 및 흡수를 향상시키고 방사성 불투과성 약제의 재흡수를 개선하기 위한 rHuPH20 제형인 Hylenex 재조합체를 제공합니다; HIV 치료를 위한 릴피비린, 카보테그라비르, N6LS BNAB, 다발성 경화증 치료제 오크레리주맙, 테스토스테론 대체 요법의 SC 투여용 주사제인 XYOSTED, 독점 약물 기기 조합 제품인 ATRS-1902를 공급합니다.
자세히 보기 Halozyme Therapeutics, Inc. 기본 사항 요약 Halozyme Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요? RV7 기본 통계 시가총액 €5.81b 수익(TTM ) €377.08m 수익(TTM ) €910.22m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) RV7 손익 계산서(TTM ) 수익 US$947.36m 수익 비용 US$249.60m 총 이익 US$697.75m 기타 비용 US$305.29m 수익 US$392.47m
주당 순이익(EPS) 3.08 총 마진 73.65% 순이익 마진 41.43% 부채/자본 비율 332.3%
RV7 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/26 23:26 장 마감 주가 2024/12/23 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Halozyme Therapeutics, Inc. 34 애널리스트 중 9 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Ishan Majumdar Baptista Research James Birchenough Barclays Robert Wasserman Benchmark Company
31 더 많은 분석가 보기 
